Literature DB >> 8668390

Unapproved uses of approved drugs: the physician, the package insert, and the Food and Drug Administration: subject review. American Academy of Pediatrics Committee on Drugs.

.   

Abstract

Physicians who prescribe a new drug that has not been approved for a specific indication or a specific age group frequently find themselves in a quandary. Physicians who prescribe "old," time-honored drugs usually do not consult the package insert or search for US Food and Drug Administration (FDA) approval. This statement was written to clarify the legal and informational status of the package insert and the role of the FDA in approving or not approving drugs for specific indications or specific age groups. The unapproved use of approved drugs, or so-called "off-label" use, is extremely prevalent among physicians who care for children. It is important that such use of compounds be brought up to date with current FDA policies and to emphasize the responsibility of the prescribing physician in the use of these compounds.

Entities:  

Mesh:

Year:  1996        PMID: 8668390

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  15 in total

1.  Status of new medicines approved by the European Medicines Evaluation Agency regarding paediatric use.

Authors:  P Impicciatore; I Choonara
Journal:  Br J Clin Pharmacol       Date:  1999-07       Impact factor: 4.335

2.  Off label prescribing in children.

Authors:  William Banner
Journal:  BMJ       Date:  2002-06-01

Review 3.  The QT interval and psychotropic medications in children: recommendations for clinicians.

Authors:  Paul McNally; Fiona McNicholas; Paul Oslizlok
Journal:  Eur Child Adolesc Psychiatry       Date:  2006-08-29       Impact factor: 4.785

4.  Package inserts and the standard of care.

Authors:  Russell G Thornton
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-10

5.  Drug investigation for Canadian children: The role of the Canadian Paediatric Society.

Authors: 
Journal:  Paediatr Child Health       Date:  2003-04       Impact factor: 2.253

6.  The plight of paediatric drug therapy.

Authors:  Stuart Macleod
Journal:  Paediatr Child Health       Date:  2011-11       Impact factor: 2.253

7.  Adolescent Human Immunodeficiency Virus Care Providers' Attitudes Toward the Use of Oral Pre-Exposure Prophylaxis in Youth.

Authors:  Tanya L Kowalczyk Mullins; Gregory Zimet; Michelle Lally; Jessica A Kahn
Journal:  AIDS Patient Care STDS       Date:  2016-07       Impact factor: 5.078

8.  Predictors of polypharmacy and off-label prescribing of psychotropic medications: a national survey of child and adolescent psychiatrists.

Authors:  Marcia A Kearns; Kristin M Hawley
Journal:  J Psychiatr Pract       Date:  2014-11       Impact factor: 1.325

9.  Unlicensed and off-label drug use: issues and recommendations.

Authors:  Sharon Conroy
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

10.  Limited capacity in US pediatric drug trials: qualitative analysis of expert interviews.

Authors:  Richard Wasserman; Alison Bocian; Donna Harris; Eric Slora
Journal:  Paediatr Drugs       Date:  2011-04-01       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.